Hospital

Axicabtagene ciloleucel (Yescarta) was the first CAR T-cell immunotherapy to be approved for relapsed or refractory large B-cell lymphoma.

Fulvestrant is also the only SERD approved for patients with breast cancer, according to the researchers.

Pharmacists can play an important role in avoiding common medication errors for patients receiving direct oral anticoagulants.

Olaparib is a first-in-class PARP inhibitor and is the first targeted treatment to block DNA damage response in cells or tumors with a deficiency in homologous recombination repair.

The investigators found that modeling was a cost-effective method for determining the functionality of the proposed blueprint by transforming it into a physical space.

Lodise discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

Although barcode scanning during product verification has greatly improved the safety of medication dispensing operations, many products aren’t easily incorporated into traditional dose preparation processes, including medications manually dispensed in oral syringes.

Acalabrutinib is a Bruton tyrosine kinase inhibitor (BTKi) intended for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

The investigators found that the ability to track the status of a medication in real-time may assist with communication gaps between departments and facilitate patient safety improvements.

Based on experience with other variants, Pfizer and BioNTech have high confidence that if needed, they can deliver an Omicron-based COVID-19 vaccine in March 2022.

Timely access to cancer treatment improves patient outcomes.

The investigators said that there were no new safety signals identified, and no reported instances of tumor lysis syndrome.

The panelists reviewed current treatments for Clostridioides difficile infection and how they can be applied to special patient populations, as well as what treatments can be expected in the future.

Rivaroxaban and apixaban are the most commonly prescribed direct oral anticoagulants, although they may be most effective in different populations.

Lodise discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

As some of the nation’s leading pharmaceutical and biotech giants ramp up product development and commercialization, what was once a futuristic concept has become a reality.

Amid the current shortage in the pharmacy technician workforce, career ladder programs could improve pharmacy technician recruitment and retention rates.

Using a non-aqueous vehicle and sweeteners to improve palatability, pharmacists and technicians can ensure that young patients remain medication adherent.

Results highlight sustained benefits of avapritinib in patients with advanced systemic mastocytosis.

Ten quiz questions to assess your knowledge on common symptoms and treatments for endometrial cancer.

Families and providers can use a flexible infusion schedule to meet patient needs, Octapharma says.

Tepotinib treats adult patients with metastatic non-small cell lung cancer harboring a mesenchymal epithelial transition exon 14 skipping alteration.

Fibromuscular dysplasia typically appears in the arteries leading to the kidneys and brain.

Assessing stroke benefit and net clinical benefit of anticoagulation is essential in patients with end-stage renal disease and atrial fibrillation.

Genomic analyses show promise for patients with metastatic breast cancer, reinforcing genomics as a part of the pathway of care.

Tamoxifen is given to many patients—specifically premenopausal patients—with breast cancers that express the estrogen receptor, which drives breast tumor growth.

Patients ages 80 and older have unique considerations when deciding whether to initiate anticoagulation therapy.

Moderna COVID-19 vaccine found to offer an increased level of protection, including a 21% reduced risk of documented infection and 41% lower risk of hospitalization.

In part 2 of the discussion, Lodise said the decision of which drugs to use for various infections is very nuanced, but the new guidance document utilized the best available evidence.

Certain patients with breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance) could benefit from an early switch to fulvestrant (Faslodex) plus palbociclib, study finds.